Journey Medical Corporation

NASDAQ:DERM

Drug Manufacturers - Specialty & Generic

Healthcare
$3.69 +0.99%

+$0.06 today

Market cap
$104.15M
Beta
1.10
P/E (TTM)
-17.0
EPS (TTM)
-$0.35
52W Low $4.31High $9.56

Volume 0.25M

Average 0.28M

DERM Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Journey Medical CorporationNASDAQ: DERM

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q1 FY2026 depreciation & amortization of $1.15M rose 5.8% year over year, behind the +16.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 5.6% from the prior quarter. Over 3 fiscal years it compounded at -0.1% a year.

Context

  • Depreciation & amortization amounted to 7.0% of revenue in FY2025, up 0.8 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +5.8% toward the trailing-twelve-month pace of +16.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.15M+5.6% QoQ
Last fiscal yearDec 2025
$4.35M+23.6% YoY
LTMMar 2026
$4.39M+16.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.8%——
1 year+23.6%——
3-year CAGR-0.1%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
4.35M USD
Year-over-year change
+23.6%
4-year CAGR
+14.1%

Depreciation & Amortization vs competitors

How DERM compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +16.5% is the 5th highest of 10, against a peer median of +13.8%.
  • Depreciation & amortization amounts to 6.8% of revenue for DERM, versus a peer median of 8.4%.
DERM Competitors
Depreciation & Amortization for DERM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OGIOrganigram Global Inc.LTM Mar 2026CA$19.76M CAD+37.8%—7.2%
OSUROraSure Technologies, Inc.LTM Mar 2026$9.54M USD+11.9%-10.7%8.4%
NYXHNyxoah S.A.LTM Mar 2026€5.27M EUR+149.9%+32.4%32.3%
DERMJourney Medical CorporationLTM Mar 2026$4.39M USD+16.5%-0.1%6.8%
IVAInventiva S.A.FY2025€2.8M EUR-46.2%+47.6%62.4%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$2.42M USD+13.8%+13.3%136.2%
MDWDMediWound Ltd.LTM Mar 2026$1.88M USD+27.6%+13.5%13.0%
HSDTSolana CompanyLTM Mar 2026$672K USD+1192.3%+38.7%7.0%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$334K USD+5.4%+13.8%1.0%
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$103K USD+0.0%-11.6%0.2%
Peer median (excluding DERM) —+13.8%+13.6%8.4%

Competitors are the stored peer set for DERM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue63.13M73.67M79.18M56.13M61.86M
Cost of Revenue32.08M30.78M26.66M20.88M25.18M
Gross Profit31.05M42.89M52.52M35.26M36.68M
Gross Margin49.2%58.2%66.3%62.8%59.3%
Research & Development16.56M10.94M7.54M9.86M480K
Selling, General & Admin39.83M59.47M43.91M40.2M44.37M
Operating Expenses65.93M70.41M54.59M48.93M44.85M
Depreciation & Amortization2.56M4.37M3.86M3.52M4.35M
EBITDA(32.77M)(23.18M)1.92M(8.4M)(3.33M)
EBITDA Margin-51.9%-31.5%2.4%-15.0%-5.4%
Operating Income(34.88M)(27.52M)(2.07M)(13.68M)(8.17M)
Operating Margin-55.2%-37.4%-2.6%-24.4%-13.2%
Interest Income2K60K322K757K589K
Interest Expense7.03M2.02M1.7M2.7M3.7M
Other Income / Expenses(7.48M)(2.05M)(1.56M)(934K)(3.2M)
Income Before Tax(42.36M)(29.57M)(3.63M)(14.61M)(11.37M)
Pre-Tax Margin-67.1%-40.1%-4.6%-26.0%-18.4%
Income Tax Expense1.63M63K221K61K60K
Net Income(43.99M)(29.63M)(3.85M)(14.67M)(11.43M)
Net Margin-69.7%-40.2%-4.9%-26.1%-18.5%
EPS (Basic)(2.54)(1.69)(0.21)(0.72)(0.47)
EPS (Diluted)(2.54)(1.69)(0.21)(0.72)(0.47)
Weighted Avg Shares17.32M17.53M18.23M20.43M24.5M
Weighted Avg Shares (Diluted)17.32M17.53M18.23M20.43M24.5M

Journey Medical Corporation

NASDAQ:DERM

Intrinsic Alpha fair value

Locked

Current Price

$3.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.